Related Articles
PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports
Long‑term survival of a <em>BRCA2</em> mutation carrier following second ovarian cancer relapse using PARPi therapy: A case report
PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review)
Pharmacological ascorbate induces ‘BRCAness’ and enhances the effects of Poly(ADP‑Ribose) polymerase inhibitors against BRCA1/2 wild‑type ovarian cancer
Poly(ADP-ribose) polymerase inhibitor olaparib hampers placental growth factor-driven activation of myelomonocytic cells